Isaac Elliott

Isaac Elliott serves as a key procurement lead within the National Institute of Allergy and Infectious Diseases (NIAID), supporting the agency’s mission to accelerate biomedical research responses to infectious, immunologic, and allergic threats. He manages the acquisition of critical research and development services focused on laboratory infrastructure, diagnostic tools, and medical countermeasures, primarily through competitive solicitation processes under FAR Part 15. His work directly enables NIAID’s strategic priorities in biosafety, biocontainment, and pandemic preparedness by securing high-performance scientific capabilities from specialized vendors. Elliott maintains a focused contractor network centered on Quality Biological, Inc., a leading provider of biological reference materials and assay development services, alongside GENOMIC LABS LTD, which supports advanced genomic analysis and sequencing capabilities. His procurement patterns reflect long-term, mission-aligned partnerships with vendors possessing specialized expertise in high-containment research support, biospecimen handling, and infectious disease diagnostics. These relationships are built on technical rigor, regulatory compliance, and consistent performance in high-stakes public health environments. His contracting approach prioritizes open competition, with approximately two-thirds of awards issued without set-aside restrictions, while maintaining a robust 33.3% commitment to total small business set-asides under FAR 19.5. This balance ensures access to innovative small firms while preserving flexibility for complex, mission-critical requirements. He consistently leverages small business capabilities without compromising technical or operational standards. Elliott’s portfolio is exclusively focused on NAICS 541715—Research and Development in the Physical, Engineering, and Life Sciences—encompassing contract research, assay validation, pathogen characterization, and laboratory system integration. His expertise lies in procuring advanced scientific services that underpin NIAID’s preclinical and translational research pipeline, particularly in virology, immunology, and high-containment biosafety Level 3 and 4 environments.